Two people with the same weight, the same health conditions, and the same prescription can get opposite answers from Medicaid purely because they live in different states. One gets Wegovy covered. The other is told it is not a benefit at all.
That is not an administrative error, and it is not something an appeal will usually fix. It comes from one line in federal law.
The line of law that does the work
Medicaid is run jointly by the federal government and the states, and states get real discretion over which drugs they pay for. Section 1927(d)(2) of the Social Security Act sets out categories a state is allowed to exclude. Sitting in that list is "agents when used for anorexia, weight loss, or weight gain."
Read that carefully, because the wording matters. It is about the drug's use, not the drug. A state can exclude semaglutide when it is prescribed for weight loss and cover the identical molecule when it is prescribed for type 2 diabetes. That is exactly what most states do.
The exclusion is permissive. No state has to use it. That single design choice is the whole reason the map looks arbitrary from the outside.
How many states actually cover it
As of January 2026, KFF counted 13 state Medicaid programs covering GLP-1s for obesity treatment under fee for service. Out of 51 programs, counting the District of Columbia, that is roughly a quarter.
It is worth sitting with that number for a second. The medicines have been available for years, the demand is enormous, and three quarters of state Medicaid programs still do not pay for them when the reason is weight.
The usual explanation is cost. GLP-1s are expensive, Medicaid budgets are set by state legislatures, and a drug that a large share of the adult population could qualify for is a serious budget line.
The states that changed their minds
The picture moved noticeably between late 2025 and early 2026, and mostly in one direction.
Ended coverage: California, New Hampshire, Pennsylvania, and South Carolina all eliminated coverage of GLP-1s for obesity treatment. California's change came after October 2025, and Medi-Cal still covers GLP-1s for type 2 diabetes.
Ended it, then brought it back: North Carolina removed coverage starting in October 2025 and reinstated it in December 2025.
Added coverage: Missouri, Tennessee, and Utah.
Narrowed the criteria: Michigan and Virginia kept coverage but tightened who qualifies.
You can check the current position for your own state on our Medicaid GLP-1 coverage pages, which carry a source and a date for every state where we have a confirmed decision.
Why we will not show you a full 50 state table
Plenty of sites publish one. We have chosen not to, and the reason is worth explaining.
KFF publishes the count and names the states that recently changed. Milliman does the same. Neither publishes the full list of 13. We checked both sources directly rather than relying on summaries of them.
That means any site showing a confident answer for all 50 states has filled in the gaps from somewhere. When we tested those sites against the two authoritative sources, we found direct contradictions, including one that listed Tennessee and North Carolina as excluding weight loss drugs when both had in fact added or restored coverage.
So for states where we can point to a source, we publish the decision and the date. For the rest, we say we do not have a confirmed decision on file and suggest checking your state Medicaid program directly. An honest gap is more useful than a confident guess about whether your medication is paid for.
Diabetes is the exception, everywhere
If you have type 2 diabetes, most of this does not apply to you. Almost every state Medicaid program covers at least one GLP-1 for type 2 diabetes. You will usually need prior approval, and many states want evidence that you tried metformin first, but the category exclusion for weight loss does not touch the diabetes indication.
The newer approvals work the same way. Wegovy's approval for reducing heart attack and stroke risk, and Zepbound's approval for moderate to severe obstructive sleep apnea, are both outside the weight loss category. We cover this in more detail in denied for weight loss, three other uses your plan may cover.
What to do if your state does not cover it
Start by confirming it rather than assuming. State policies changed several times in the last year, in both directions, and front line staff do not always have the current position. Your state Medicaid program's member services line is the authority.
If weight loss genuinely is excluded, an appeal on medical necessity will not usually succeed, because the exclusion is a category decision rather than a judgement about your health. Ask your clinician whether another documented condition applies instead.
And if none does, cash pay is the remaining route. Our pricing guide sets out what GLP-1 treatment actually costs without insurance, and you can compare clinics near you.
Sources: KFF, Medicaid coverage of and spending on GLP-1s, coverage counts as of January 2026; Milliman, the evolving landscape of anti-obesity medication coverage in Medicaid, for the states that changed; Social Security Act section 1927(d)(2). This is general information, not medical or insurance advice.
Frequently asked questions
Can my state add coverage later?
Yes, and several have. Missouri, Tennessee, and Utah all added coverage recently, and North Carolina restored it within a couple of months of dropping it. These are state budget decisions, so they can change with a legislative session.
If I move states, does my coverage move with me?
Medicaid eligibility and benefits are state specific, so you would apply in your new state and get that state's rules. This is one of the few situations where moving genuinely changes whether a medicine is paid for.
Does this affect Medicare too?
No. Section 1927(d)(2) is a Medicaid rule and Medicare runs under its own. Weight loss drugs were shut out of Part D for years, but since July 1, 2026 the Medicare GLP-1 Bridge has covered Wegovy and Zepbound at a flat $50 a month for eligible enrollees, through December 31, 2027. See our Medicare GLP-1 coverage page.
Why is my managed care plan's answer different from the state's?
Most Medicaid enrollees are in managed care plans, and those plans can run their own drug lists within the state's rules. The KFF count tracks fee for service, so your managed care plan's list is worth checking separately.